Enrolling by invitationPhase 3NCT04976322
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Studying Systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UCB Biopharma SRL
- Principal Investigator
- UCB Cares001 844 599 2273 (UCB)
- Intervention
- Dapirolizumab pegol(drug)
- Enrollment
- 760 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2021 – 2030
Study locations (30)
- Sl0046 50140, Birmingham, Alabama, United States
- Sl0046 50328, Tucson, Arizona, United States
- Sl0046 50383, Beverly Hills, California, United States
- Sl0046 50275, La Palma, California, United States
- Sl0046 50316, San Leandro, California, United States
- Sl0046 50339, Denver, Colorado, United States
- Sl0046 50239, Brandon, Florida, United States
- Sl0046 50362, Gainesville, Florida, United States
- Sl0046 50681, Miami, Florida, United States
- Sl0046 50059, Ormond Beach, Florida, United States
- Sl0046 50324, Plantation, Florida, United States
- Sl0046 50329, Tampa, Florida, United States
- Sl0046 50368, Atlanta, Georgia, United States
- Sl0046 50240, Idaho Falls, Idaho, United States
- Sl0046 50474, Hopkinsville, Kentucky, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04976322 on ClinicalTrials.govOther trials for Systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGNANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPHASE3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc.
- RECRUITINGEARLY PHASE1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEARLY PHASE1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology